Identification of 2-Aminothiazole-4-Carboxylate Derivatives Active against Mycobacterium tuberculosis H37Rv and the β-Ketoacyl-ACP Synthase mtFabH
Open Access
- 19 May 2009
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 4 (5), e5617
- https://doi.org/10.1371/journal.pone.0005617
Abstract
Tuberculosis (TB) is a disease which kills two million people every year and infects approximately over one-third of the world's population. The difficulty in managing tuberculosis is the prolonged treatment duration, the emergence of drug resistance and co-infection with HIV/AIDS. Tuberculosis control requires new drugs that act at novel drug targets to help combat resistant forms of Mycobacterium tuberculosis and reduce treatment duration. Our approach was to modify the naturally occurring and synthetically challenging antibiotic thiolactomycin (TLM) to the more tractable 2-aminothiazole-4-carboxylate scaffold to generate compounds that mimic TLM's novel mode of action. We report here the identification of a series of compounds possessing excellent activity against M. tuberculosis H37Rv and, dissociatively, against the β-ketoacyl synthase enzyme mtFabH which is targeted by TLM. Specifically, methyl 2-amino-5-benzylthiazole-4-carboxylate was found to inhibit M. tuberculosis H37Rv with an MIC of 0.06 µg/ml (240 nM), but showed no activity against mtFabH, whereas methyl 2-(2-bromoacetamido)-5-(3-chlorophenyl)thiazole-4-carboxylate inhibited mtFabH with an IC50 of 0.95±0.05 µg/ml (2.43±0.13 µM) but was not active against the whole cell organism. These findings clearly identify the 2-aminothiazole-4-carboxylate scaffold as a promising new template towards the discovery of a new class of anti-tubercular agents.This publication has 27 references indexed in Scilit:
- Separate Entrance and Exit Portals for Ligand Traffic in Mycobacterium tuberculosis FabHCell Chemical Biology, 2008
- Structure−Activity Relationships at the 5-Position of Thiolactomycin: An Intact (5R)-Isoprene Unit Is Required for Activity against the Condensing Enzymes from Mycobacterium tuberculosis and Escherichia coliJournal of Medicinal Chemistry, 2005
- Antitubercular agents. Part 2: New thiolactomycin analogues active against Mycobacterium tuberculosisBioorganic & Medicinal Chemistry Letters, 2005
- The search for new sterilizing anti-tuberculosis drugsFrontiers in Bioscience-Landmark, 2004
- Mycolic acid biosynthesis and enzymic characterization of the β-ketoacyl-ACP synthase A-condensing enzyme from Mycobacterium tuberculosisBiochemical Journal, 2002
- Purification and Biochemical Characterization of theMycobacterium tuberculosis β-Ketoacyl-acyl Carrier Protein Synthases KasA and KasBPublished by Elsevier BV ,2001
- Inhibition of β-Ketoacyl-Acyl Carrier Protein Synthases by Thiolactomycin and CeruleninPublished by Elsevier BV ,2001
- Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequenceNature, 1998
- MOLECULAR RECOGNITION OF RECEPTOR-SITES USING A GENETIC ALGORITHM WITH A DESCRIPTION OF DESOLVATIONJournal of Molecular Biology, 1995
- The preparation of thiazole-4- and -5-carboxylates, and an infrared study of their rotational isomersJournal of the Chemical Society, Perkin Transactions 1, 1982